Compare · GLP-1 agonist
Mazdutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Mazdutide | Semaglutide | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that activates two metabolic hormone receptors at once. Unlike most of the attention-grabbing GLP-1 compounds, it is not stuck at the press-release stage: it has a published Phase 3 trial in a major journal and is actually approved…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.